Vaginal Cancer – Pipeline Review, H2 2017 – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Vaginal
Cancer – Pipeline Review, H2 2017”
report has been added to Research
and Markets’
offering.

Vaginal Cancer – Pipeline Review, H2 2017, provides comprehensive
information on the therapeutics under development for Vaginal Cancer
(Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Vaginal Cancer (Oncology) pipeline guide also reviews of key players
involved in therapeutic development for Vaginal Cancer and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Phase II, Phase I and Preclinical stages are
4, 1 and 1 respectively.

Vaginal Cancer (Oncology) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Vaginal Cancer – Overview
  3. Vaginal Cancer – Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Vaginal Cancer – Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Vaginal Cancer – Companies Involved in Therapeutics Development
  • ISA Pharmaceuticals BV
  • MedImmune LLC
  • Ology Bioservices Inc
  • Ono Pharmaceutical Co Ltd
  • Oryx GmbH & Co KG
  • Taiwan Liposome Company Ltd

For more information about this report visit https://www.researchandmarkets.com/research/t2bsmh/vaginal_cancer?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Women’s
Health
, Cervical
Cancer Drugs